We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Interim guidance and information on the law for healthcare professionals
The Home Secretary has formally commissioned the Advisory Council on the Misuse of Drugs (ACMD) to conduct a longer-term review of cannabis-based products for medicinal use.
The therapeutic and medicinal benefits of cannabis-based products – a review of recent evidence.
An assessment of the impact of rescheduling CBPMs to Schedule 2 under the Misuse of Drugs Regulations 2001 (MDR) and recommendations to mitigate the issues identified.
Advisory Council on the Misuse of Drugs (ACMD) call for evidence on cannabinoids in CBD products.
Patients prescribed cannabis-based medicines will be able to get their treatment in days rather than months.
The ACMD has recommended that cannabis-derived medicinal products should be placed in Schedule 2 of the Misuse of Drugs Regulations 2001.
Employment Tribunal decision.
Specialist clinicians will be able to legally prescribe cannabis-derived medicinal products by the autumn, Home Secretary Sajid Javid announced today.
Home Secretary to receive advice on cannabis-related medicinal products.
In 2008 MHRA commissioned Ipsos MORI to research the public’s perception of herbal medicines, the findings may help doctors and pharmacists when considering how to advise patients.
Home Secretary responds to the recommendations of the Advisory Council on the Misuse of Drugs about scheduling of cannabis-derived medicinal products.
Home Secretary writes to the chair of the Advisory Council on the Misuse of Drugs about scheduling of cannabis-derived medicinal products.
Advice from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the scheduling of cannabis-derived medicinal products.
The Advisory Council on the Misuse of Drugs response to the consultation by NICE on the draft scope of their guidance on cannabis-based products for medicinal use.
Further advice from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the scheduling of cannabis-derived medicinal products.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).